Clinical research
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
Uveal melanoma is a rare and aggressive form of melanoma. It primarily affects the eye. There are no currently accepted optimal management regimens or treatments.
AstraZeneca and the University of Oxford announced results from an interim analysis of their COVID-19 vaccine, AZD1222. The analysis was from the trials in the UK and Brazil and demonstrated efficacy of up to 90%.
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look.
The U.S. Food and Drug Administration has accepted ADC Therapeutics’ Biologics License Application (BLA) and granted priority review for the company’s relapsed/refractory diffuse large B-cell lymphoma (DLBCL) treatment, loncastuximab tesirine (Lonca).
The World Health Organization (WHO) recommends against using Gilead Sciences’ remdesivir as a treatment for COVID-19.
As expected after Pfizer and BioNTech announced their COVID-19 vaccine Phase III trial had completed and demonstrated a 95% efficacy rate, the companies plan to apply for an Emergency Use Authorization (EUA) with the FDA.
Positive top-line data from UniQure’s Phase III HOPE-B gene therapy trial of etranacogene dezaparvove, an investigational AAV5-based gene therapy, point to a potentially curative treatment for patients with moderate to moderately severe hemophilia B.
AstraZeneca and the University of Oxford published Phase II clinical trial results for their COVID-19 vaccine in The Lancet. The data shows the vaccine is safe and offers a similar immune response in all adults.
PRESS RELEASES